Sun et al. [153] demonstrated that Nrf2 activator RTA-408 increases the expression of GPx4 and SLC7A11, increasing GSH production, with a significant decrease in oxidative stress alleviating neurodegeneration and symptoms in ALS animal models. Here, GPX4 is linked to amyotrophic lateral sclerosis.